-+ 0.00%
-+ 0.00%
-+ 0.00%

Novartis' Polymyalgia Rheumatica Drug Wins US FDA Nod

MT Newswires·11/16/2026 23:19:53
Listen to the news
11:19 PM EST, 11/16/2026 (MT Newswires) -- Novartis (NOVN.SW) secured the US Food and Drug Administration's approval for its Cosentyx drug as an alternative to long-term steroid use for adults with polymyalgia rheumatica. The Swiss pharmaceutical company said Tuesday that Cosentyx, or secukinumab, doubled sustained remission rates while helping patients taper off steroids in the phase 3 Replenish trial. The approval makes Cosentyx the first and only anti-interleukin-17 biologic approved for patients with the common inflammatory disease, which mostly affects adults aged 50 and older.